{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-092042","form_type":"8-K","ticker":null,"cik":"0001213660","company_name":"BIMI Holdings Inc.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.446380+00:00","generated_at":"2026-06-07T19:12:14.261539+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BIMI International Medical restates multiple quarters; material weakness in internal controls","bullets":["Audit committee concludes FY2022 and Q1-Q3 2022 and Q1 2023 financials should no longer be relied upon due to errors in equity, notes, acquisitions, and cash flows.","Errors include misclassification of $5M convertible note, incorrect accounting for Phenix Bio acquisition deposit, and misstated discontinued operations cash flows.","Management identifies material weakness in internal controls; disclosure controls ineffective as of multiple dates.","Restatements do not materially affect net income, liquidity, or debt covenants according to the company.","Company plans to file amended 10-K and 10-Qs and hire new consulting firm to strengthen internal controls."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-092042","json":"https://secwatch.observer/filing/0001213900-23-092042.json","markdown":"https://secwatch.observer/filing/0001213900-23-092042.md","text":"https://secwatch.observer/filing/0001213900-23-092042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213660/000121390023092042/0001213900-23-092042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213660/000121390023092042/ea189175-8k_bimiinter.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:12:14.261539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c07e8cc52590831af9abd84c776bb8372eeadafc","claim":"BIMI Holdings Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"each, a “Form 10-Q,” together with the 2022 Form 10-K, the “Affected Reports”), should no longer be relied upon due to certain errors and incorrect disclosures contained in the Affected Reports. The Company concluded that the restatements do not materially affect the Company’s liquidity or its compliance with debt covenants or other financial obligations. The Company intends to restate the Affected Reports to address these issues as follows. (1) The Company is in the process of restating the Consolidated Statements of Equity for the quarterly periods ended June 30, 2022 and September 30, 2022. The restatement relates to the stockholders’ equity and noncontrolling interests presented in the Consolidated Balance Sheets, as of June 30, 2022 and September 30, 2022, which had been presented in the form of a reconciliation of the beginning balance to the ending balance for each period for whic","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213660/000121390023092042/0001213900-23-092042-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}